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High-dose therapy and autologous stem cell transplantation (ASCT) have proven efﬁcacy in patients with
multiple myeloma responding well to induction therapy. For those who fail to achieve a stable partial
response (PR), the effect of ASCT is unclear. We report on 126 patients identiﬁed from a national database,
who underwent ASCT having achieved <PR after induction with modern induction regimens. The overall
response rate was 86% (24% complete response). Patients with progressive disease at the time of trans-
plantation had poorer outcomes than those with minimally responsive or stable disease, but clinical beneﬁt
was seen in all groups. Day 100 and 1-year nonrelapse mortalities were 2% and 4%, respectively. The 5-year
relapse rate and progression-free survival were 84% and 14% (median, 18 months), respectively. The 5-year
overall survival was 42% (median, 51 months). Our ﬁndings support the use of ASCT in myeloma patients
responding suboptimally to modern induction therapies. Patients should not be excluded on the basis of
refractoriness to induction, as ASCT is effective in this group conventionally considered to have a poor
outcome. Comprehensive multivariate analysis identiﬁed no disparate subgroups, meaning ASCT is a
reasonable strategy for all ﬁt primary refractory patients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION (PRM) (43 and 50 patients, respectively) who received ASCT
Since the initial demonstration of high-dose melphalan
for multiple myeloma (MM), in excess of 500 reports have
been published on its use, with nearly 15,000 patients un-
dergoing autologous stem cell transplantation (ASCT) in
Europe. Randomized controlled studies show improved
response rates, progression-free survival (PFS), and overall
survival (OS) comparedwith conventional chemotherapy [1].
ASCT has, therefore, become the established front-line
therapy for those biologically ﬁt enough for its physiolog-
ical challenges. The depth of response to induction therapy is
correlated with outcome after ASCT; attainment of at least a
very good partial response (PR) is associated with superior
PFS [2]. However, even with novel agentecontaining induc-
tion regimens, up to 25% of newly diagnosed patients have
poorly responsive disease (<PR), and this proportion rises
with sequential relapses.
Studies in other refractory B cell malignancies (eg, non-
Hodgkin lymphoma) have yielded disappointing results
with ASCT [3]. However, this may not be the case for
MMdthe few published reports are conﬂicting and largely
predate novel agents. In the early 2000s, Singhal et al. and
Kumar et al. reported cohorts with primary refractory MMedgments on page 1333.
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15.03.026after conventional induction therapy [4,5]. They found no
difference in long-term outcomes compared with patients
undergoing ASCT with chemo-sensitive disease. In contrast,
in a post hoc analysis of the IFM 2005-01 trial, Moreau et al.
reported failure to achieve very good PR after bortezomib-
based induction resulted in inferior PFS after ASCT [2].
Nonetheless, even if outcomes of ASCT for<PR are inferior to
those of ASCT forPR, the modality might nevertheless offer
clinical beneﬁt.
We sought to delineate the clinical course of patients who
underwent ASCT despite failing to achieve a PR after induc-
tion with modern therapies. Patients were identiﬁed as
having achieved minimal response (MR), stable disease (SD),
or progressive disease (PD) at the time of ASCT. In this report,
we examine the impact of ASCT and discuss the clinical
utility of ASCT for aggressive and poorly responding disease.DESIGN AND METHODS
Patient Selection, Deﬁnitions, and Procedures
This retrospective study was approved and registered by the British
Society of Blood and Marrow Transplantation Clinical Trials Committee.
Eligible patients were identiﬁed from the British Society of Blood and
Marrow Transplantation Data Registry. Consent was obtained at the time of
transplantation, in line with European Bone Marrow Transplant Registry
directives with European Bone Marrow Transplant response criteria [6]
were used throughout, as the majority of patients underwent trans-
plantation in or before 2006, when the more recent International Myeloma
Working Group criteria were published. Patients were eligible if, at the time
of ASCT, they had never achieved PR (ie, best response was MR, SD, or PD)
and had undergone stem cell collection sufﬁcient to undertake ASCT, by
either peripheral apheresis or bone marrow harvesting. Bone marrow
aspirate and trephine biopsy was performed at 100 days after trans-
plantation, unless declined.
Table 1
Patient Characteristics and Response to ASCT at Day 100
Characteristics Value




Age at diagnosis, median (range), yr 54 (25-69)
Age at transplantation, median (range), yr 56 (33-72)
Time from ﬁrst treatment to transplantation,
median (range), mo
7 (3-73)
>12 months (%) 16





Karnofsky status at transplantation, n (%)
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Metrics collected for all patients were as follows: age at diagnosis, age at
ASCT, gender, Karnofsky status at ASCT, b2-microglobulin at diagnosis, al-
bumin at diagnosis, serum creatinine at diagnosis, serum creatinine at ASCT,
number of lines of prior therapy, disease status at time of ASCT, time from
diagnosis to ASCT, time from ﬁrst therapy to ASCT, and ASCT conditioning
regimen. The Kaplan-Meier product-limit estimator was used for median
and range of the follow-up time and univariate (UVA) probabilities. Non-
relapse mortality (NRM), relapse, PFS, and survival after ASCT were evalu-
ated in multivariate analyses (MVA) using competing risk analysis to
identify patient-, disease-, and transplantation-related variables prognostic
of outcomes (relapse and NRM were used as competing risks for each
another). The assumption of proportional hazards for each factor in the Cox
model was tested using time-dependent covariates. For nonproportional
hazards, the post-transplantation time course was broken into 2 periods,
using the maximized partial likelihood method to ﬁnd the most appropriate
breakpoint. Interactions between covariates were tested before stepwise
modeling. The ﬁnal MVA model was built using a forward stepwise model.
































High-dose therapy regimen, n (%)RESULTS
Patients
One hundred twenty-six eligible patients were identiﬁed
and underwent transplantation between 2000 and 2008 at
18 centers in the United Kingdom. Patient and trans-
plantation characteristics are shown in Table 1. All patients in
this study had primary refractory disease, having failed to
achieve at least a PR in response to any and all prior thera-
pies; 67 (53%) patients received ASCT “up front” after 1 line
of induction therapy resulting in <PR (including 11 patients
with PD during induction); 59 (47%) received ASCT after
more than 1 cycle of therapy, again having never achieved a
PR or better in response to any therapy. Induction regimens
were not standardized but were in keeping with current
United Kingdom practice during that time period, and,
therefore, some incorporated thalidomide but not lenalido-
mide or bortezomib. No patients had received prior ASCT.
Cytogenetic data were available for too few patients to allow
subgroup analysis. Median time to engraftment (deﬁned as
peripheral blood neutrophils > .5  109/L) was 14 days
(range, 9 to 117) and platelet engraftment (>50  109/L un-
supported) was 19 days (range, 10 to 132). Median follow-up
is 61 months (range, 1 to 112).Melphalan 200 mg/m2 62 (52)
Melphalan 140 mg/m2 16 (13)
Melphalan 100 mg/m2 8 (6)
Melphalan other dose 34 (27)
Unknown 6
Stem cell source, n (%)
Peripheral blood 123 (98)
Bone marrow 2 (2)
Combination of both 1 (1)
Response to transplantation at day 100, n (%)NRM
Three of 126 evaluable patients died of treatment-related
causes within 100 days. NRM at 100 days, 1 year, and 5 years
were 2%, 4%, and 10%, respectively. UVA and MVA are shown
in Table 2 (variables listed as collected in the Methods sec-







Death (ASCT-related) 3 (3)
Unknown 6 (6)
ISS indicates International Scoring System.Response to ASCT and Relapse Rate
At day 100, the complete response (CR) rate was 21% (95%
conﬁdence interval [CI], 13% to 29%) and the PR rate was 74%
(95% CI, 65% to 82%) (Table 1). Response rate was not corre-
lated with any demographic or treatment factors. Patients
with MR or SD at the time of transplantation demonstrated a
CR rate of 24% and PR rate of 70%, compared with those with
PD at the time of transplantation, who had 16% and 79%,
respectively (P ¼ .608). Disease response at day 100 (CR
versus PR versus PD) was strongly predictive of OS, PFS, and
relapse rate (P ¼ .02, P ¼ .003, P ¼ .003, respectively). Given
that administration of high-dose melphalan is the rationale
for ASCT, UVA and MVA for response rate, OS, PFS, and
relapse rate by melphalan dose were untaken and did not
reach signiﬁcance.At the time of analysis, 65 patients had died at amedian of
25 months after ASCT (95% CI, 19 to 35): 54 were due to
disease progression and 11 unrelated causes. The relapse
rates at 1 year and 5 years were 33% and 84%, respectively. PD
at the time of transplantation conferred an increase in rate of
relapse (47% at 1 year, comparedwith 18% and 20% for SD and
MR, respectively, P ¼ .022).
Table 2
Univariate and Multivariate Analysis for OS, Response Rate, PFS, NRM, and
Relapse Rate
Outcome Variable P Value
OS Disease status at transplantation .012
PFS Albumin at diagnosis (continuous) .042
Karnofsky status at transplantation .005
Disease status at transplantation .003
Disease response at day 100* .003
Albumin at diagnosis (continuous) (MVA) .033
Karnofsky status at transplantation (MVA) .040
NRM Albumin at diagnosis (continuous) .021
Albumin at diagnosis (continuous, MVA) .021
Relapse rate Karnofsky status at transplantation .002
Creatinine at diagnosis (continuous) .037
Disease status at transplantation .009
Disease response at day 100* .003
Karnofsky status at transplantation (MVA) .007
Disease response at day 100 (MVA)* .002
All P values are for UVA, unless speciﬁed.
* Patients surviving beyond day 100 only.
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The PFS at 5 years was 15% (95% CI, 9% to 23%), with a
median PFS of 18 months (range, 15 to 21) (Figure 1). OS at 5
years was 42% (95% CI, 32% to 52%), with a median OS of 51
months (range, 44 to 62) (Figure 1).DISCUSSION
Induction therapy followed by consolidation with high-
dose therapy and ASCT is currently standard practice for ﬁt
patients with responsive disease [1]. However, in those
responding suboptimally to modern induction regimens, the
role of ASCT is unclear and little evidence exists as to which
patients might beneﬁt.
Our data clearly show that for patients whose disease
response before ASCT was<PR, ASCT is an effective means of
inducing a deeper remission, with overall response rates of
86%. This is in contrast to previous reports suggesting pa-
tients with disease poorly responsive to conventional regi-
mens do not gain clinically useful responses from ASCT [7].
This is extremely important, since depth of response in MMFigure 1. Kaplan-Meier estimates. (A) Shows PFS by disease status at tranis nowwell recognized to predict PFS and OSdindeed, in our
cohort, depth of response at day 100 correlated with the
relapse rate. Patients with PRM had a shorter median PFS
than published reports of those who underwent trans-
plantation in PR, but this nevertheless translated into a
good 5-year OS in an otherwise difﬁcult-to-manage group of
patients [8,9]. Of course, this OS is partially reﬂective of ad-
vances in salvage therapy employed at relapse, just as in
ASCT for responsive disease; the combination of ASCT and
these agents should be considered additive rather than
mutually exclusive. It is also worthy of note that although
52% of the patients in our cohort received melphalan 200
mg/m2, the remainder were treated with lower doses, which
would be expected to reduce the efﬁcacy of the treatment.
Our results may, therefore, actually underestimate the efﬁ-
cacy of ASCT with “full-dose” melphalan for PRM. Reassur-
ingly, within our cohort the 1- and 5-year NRM were 4% and
10%dsimilar to ASCT for responsive disease [1,10].
OS, PFS, and relapse rate were correlated with disease
status at transplantation, with patients achieving MR or SD
faring better than those with PD, although clinically useful
responses were still seen in those patients with PD. These
ﬁndings are in keeping with a recent demonstrating poor
outcomes for patients with PD (PFS and OS of 7 and 13
months, respectively) [11].
Naturally, there are some limitations inherent to a
retrospective analysis. First, induction regimens were not
standardized but were in keeping with United Kingdom
practice during the time frame of data capture. Some
induction regimens included thalidomide, and when prior
exposure to thalidomide was examined in UVA and MVA, no
signiﬁcant effect on outcomes was seen. However, outside of
clinical trials, bortezomib and lenalidomide became available
to UK National Health Service patients in 2007 and 2009,
respectively, and consequently none of the included patients
had received these agents. Although the inclusion of these
novel agents has undoubtedly improved response rates, a
proportion of patients nevertheless do not achieve PR
[12,13], and our data are relevant to this group. In addition,
thalidomide-based induction regimens continue to be
widely employed, and this is likely to remain the case insplantation and (B) shows OS by disease status at transplantation.
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limited outside clinical trials.
Secondly, information on maintenance therapy and
subsequent salvage regimens was unavailable; cytogenetic
stratiﬁcationdatawerealsonot available for themajorityofour
patients. A major obstacle to evaluating ASCT for PRM is that
the prognosis with nontransplantation therapies is also
unknown. Alexanian et al. reported 27 patients receiving ASCT
and60receivingnontransplantation therapies:ASCT improved
median survival by 27months (P< .01) [14]. In that era, neither
induction nor salvage regimens incorporated novel agents, the
numbers were small, and the control arm received suboptimal
therapy for socioeconomic reasons; nevertheless, a clear
beneﬁt was shown. Early phase studies evaluating novel
and experimental therapies in relapsed refractory MM are
myriad, and although cautious interpretation is warranted
with such heterogeneous populations, it is clear that the
outcomes for this group of patients remain generally poor
despite advances in therapy. For example, consider 4 recent
early phase studies that have evaluated carﬂizomib-
lenalidomide-dexamethasone [15], pomalidomide-
bortezomib-dexamethasone [16], elotuzumab-bortezomib
[17], and vorinostat-bortezomib [18] in relapsed refractory
populations after a median of 2 lines of prior therapy, and
found PFS of 11.8 months, 7.4 months (duration of response
rather than PFS), 9.7 months, and 7.6 months, respectively.
Clearly such studies do not represent a comparator group for
our cohort but do illustrate that even the next generation of
novel agents does not mitigate the adverse prognosis of dis-
ease refractory to current induction regimes.
A prospective comparison of ASCT to modern non-ASCT
therapy in patients with PRM would be extremely informa-
tive, particularly in light of the often poor durability of re-
sponses to novel agents at relapse [19]. Nonetheless, it seems
fair to conclude that even with a new array of treatment
modalities becoming available, the outlook for patients with
PRM receiving nontransplantation therapy is poor, and in
this context ASCT represents a highly attractive option for
establishing disease control. In addition, use of ASCT does not
preclude subsequent treatment with experimental agents,
which might well be incorporated into maintenance regi-
mens or employed at later relapse.
Our ﬁndings support the use of ASCT in myeloma patients
responding suboptimally to modern induction therapies,
including thalidomide-containing regimens. Patients should
not be excluded on the basis of refractoriness to induction, as
ASCT is effective in this group conventionally considered to
have a poor outcome. Comprehensive MVA identiﬁed no
disparate subgroups, meaning ASCT is a reasonable strategy
for all ﬁt primary refractory patients.
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Telomere lengtha b s t r a c t
Cord blood (CB) leukocytes have inherent telomere length (TL) variation, and CB hematopoietic stem cells
(HSC) can maintain high telomerase levels preventing telomere attrition in vitro. We evaluated TL changes in
13 adult double-unit CB transplant (CBT) recipients. In the 26 units, we observed a marked variation in CB TL
at thaw (median, 9.99 kilobases [kb]; range, 6.85 to 13.5). All 13 patients engrafted. Of 11 engrafting with 1
unit, there was no correlation between unit dominance and TL (mean dominant unit TL, 8.84 kb  1.76; mean
nonengrafting unit TL, 10.3 kb  1.81; P ¼ .77). Serial measurements of TL up to 1 year after CBT demonstrated
an overall mean 3.04 kb  .16 TL decrease with only 1 patient exhibiting telomere maintenance. In summary,
initial TL does not predict CB unit dominance. Moreover, our analysis suggests neonatal hematopoiesis makes
a transition to an HSC characterized by changes in average TL and potentially low telomerase asymmetric cell
division in adult CBT recipients. Further investigation of alterations in telomere length and its clinical im-
plications after transplantation of this observation are indicated.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION there is an inherent biological variation at birth. We have
Cord blood (CB) is an alternative source of allogeneic
hematopoietic stem cells (HSC) for the transplantation of
patients lacking suitable HLA-matched adult donors.
Although CB transplantation (CBT) has the advantage of
reduced stringency of requiredHLAmatch, it is limited by the
low progenitor cell dose, resulting in impaired engraftment
and restricting the application of CBT in larger children and
adults. One strategy to extend transplantation access in adult
patients is to combine 2 units in a double-unit graft [1].
Intriguingly, a single unit mediates sustained donor hema-
topoiesis in the majority of patients. However, the mecha-
nisms of unit dominance have not been fully elucidated.
Furthermore, although healthy long-term survivors of CBT
are documented, the long-term effects of transplanting a
limited number of HSC from a CB unit into adult recipients
have not been fully established.
It is known that CB progenitors have a signiﬁcantly
higher replicative potential than adult HSC [2], althoughpreviously shown that CB demonstrates maintenance of
telomere length (TL) in vitro due to persisting levels of
telomerase activity for 4 to 5 months [3]. The effect of
replicative stress in vivo on TL, however, is unknown. We,
therefore, investigated the extent of TL variability in
clinical CB units, the inﬂuence of TL upon unit dominance
after CBT, and the effect of the in vivo microenvironment
on the degree of neonatal TL changes during the ﬁrst
post-transplantation year in adult double-unit CBT
recipients.
STUDY DESIGN
Thirteen patients with high-risk hematologic malignancies under-
went transplantation with 4 to 6 of 6 HLA-A, -B antigen, -DRB1
allele-matched unrelated donor double-unit CB grafts after myeloablative
or nonmyeloablative conditioning, as previously described [4-6]. All
patients provided informed consent for transplantation in accordance
with the Declaration of Helsinki and signed institutional review
boardeapproved consent for the laboratory analysis of each CB unit and
serial peripheral blood samples. Each CB unit was analyzed on the same
day as clinical transplantation. Mononuclear cells (MNCs) were isolated
from each unit and from peripheral blood at days 28, 100, 180, and 1 year
after CBT by density gradient separation with Ficoll-Hypaque. DNA was
then isolated from MNC pellets and quantiﬁed using a BioTek Synergy H1
Hybrid Multi-Mode Microplate Reader (BioTek, Winooski, VT). Southern
Blot was performed using the Roche TeloTAGGG Telomere Length Assay
(Roche Diagnostics GmBH, Mannheim, Germany) per the manufacturer’s
instructions. Clinical engraftment was evaluated after transplantation
